Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent

Circ Cardiovasc Interv. 2021 Mar;14(3):e010144. doi: 10.1161/CIRCINTERVENTIONS.120.010144. Epub 2021 Mar 1.

¹ Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York (A.J.K.).
² Baylor Scott & White Heart and Vascular Hospital, Dallas, TX (R.S., J.W.C.).
³ MediQuest Research at AdventHealth Ocala, FL (R.F.).
⁴ University of Freiburg, Universitats-Herzzentrum Freiburg, Bad Krozingen, Germany (F.-J.N.).
⁵ North Shore University Hospital, Manhasset, NY (L.B.).
⁶ Oklahoma Heart Hospital, Oklahoma City (N.T.).
⁷ Herzzentrum Segeberger Kliniken, Bad Segeberg, Germany (R.T.).
⁸ Duke University Health System, Durham, NC (I.O.).
⁹ Morton Plant Mease Healthcare System, Clearwater, FL (B.S.).
¹⁰ Bern University Hospital, Inselspital, University of Bern, Switzerland (S.W.).
¹¹ Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.).
¹² University of Vermont Medical Center, Burlington (H.L.D.).
¹³ Scripps Clinic, La Jolla, CA (M.J.P.).
¹⁴ Boston Scientific Corporation, Marlborough, MA (P.U., D.A., I.M.).
¹⁵ Lindner Center for Research and Education at Christ Hospital, Cincinnati, OH (D.J.K.).

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT02605447.

Keywords: aspirin; everolimus; percutaneous coronary intervention; stent; thrombosis.